Login
Toggle sidebar

Lint: 177lu-dotatate

177lu-dotatate
Acronyms
warning

"Lutetium-177 dotatate, also known as Lu-177 oxodotreotide and by the trade name Lutathera (Novartis Pharmaceuticals Corporation, USA), is a theranostic agent approved as a second-line agent for the treatment of patients with inoperable and/or metastatic well-differentiated neuroendocrine tumours involving the pancreas or gastrointestinal tract (GEP-NETs). The treatment works by utilising DOTA-TATE, a molecule with affinity for the somatostatin receptor SSTR2, fused to the radioactive molecule Lutetium-177, which kills tumour cells."

Line 1:184 · 'USA' has no definition. Spell it out if it's unfamiliar to the audience.

"Lutetium-177 dotatate, also known as Lu-177 oxodotreotide and by the trade name Lutathera (Novartis Pharmaceuticals Corporation, USA), is a theranostic agent approved as a second-line agent for the treatment of patients with inoperable and/or metastatic well-differentiated neuroendocrine tumours involving the pancreas or gastrointestinal tract (GEP-NETs). The treatment works by utilising DOTA-TATE, a molecule with affinity for the somatostatin receptor SSTR2, fused to the radioactive molecule Lutetium-177, which kills tumour cells."

Line 1:416 · 'GEP' has no definition. Spell it out if it's unfamiliar to the audience.

"The standard of care treatment for inoperable well-differentiated neuroendocrine tumours is a long-acting somatostatin analogue such as octreotide. The multicentric NETTER-1 trial phase III study initially demonstrated significantly longer progression-free survival in a population of 229 patients when comparing treatment with Lu-177 DOTATATE plus standard of care versus standard of care alone. However, no statistically significant overall survival (48 months versus 36.3 months) was found. This difference of 11.7 months can still be clinically relevant."

Line 23:169 · 'NETTER' has no definition. Spell it out if it's unfamiliar to the audience.

"Lu-177 DOTATATE was approved for medical use in adults with inoperable or metastatic GEP-NETs by the European Medicines Agency in 2017 and by the FDA in 2018."

Line 24:89 · 'GEP' has no definition. Spell it out if it's unfamiliar to the audience.

"Lu-177 DOTATATE was approved for medical use in adults with inoperable or metastatic GEP-NETs by the European Medicines Agency in 2017 and by the FDA in 2018."

Line 24:150 · 'FDA' has no definition. Spell it out if it's unfamiliar to the audience.
Strong
warning

"Characteristics "

Line 2:5 · Generally, don't use bold in text: 'Characteristics<strong> </strong>'
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Characteristics "

Line 2:1 · "Characteristics<strong> </strong> " is not a recognised heading for this article type.

"Use"

Line 10:1 · "Use" is not a recognised heading for this article type.

"Potential side effects"

Line 14:1 · "Potential side effects" is not a recognised heading for this article type.
Semicolons
suggestion

"rare: liver damage; more common in patients with hepatic tumour burden"

Line 18:26 · Use semicolons judiciously.
Links
0
0
0
0
0
0
0
0
0
0
0
0